|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.140 EUR | +0.78% |
|
-3.75% | -24.85% |
| Mar. 25 | Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Jan. 20 | Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment | MT |
Company Valuation: Hyloris Pharmaceuticals SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 245.4 | 446.9 | 310.9 | 357 | 183.1 | 143.9 | 143.9 | - |
| Change | - | 82.11% | -30.44% | 14.84% | -48.71% | -21.41% | 0% | - |
| Enterprise Value (EV) 1 | 181.6 | 408.7 | 267.8 | 328.1 | 161.3 | 179.4 | 140.6 | 106.4 |
| Change | - | 125.07% | -34.46% | 22.48% | -50.82% | 11.17% | -7.01% | -24.32% |
| P/E ratio | -28.8x | -38.4x | -29x | -23.2x | -28.4x | -29.7x | -23.6x | 10.1x |
| PBR | 4.09x | 9.3x | 5.73x | - | - | 5.55x | 5.88x | 3.51x |
| PEG | - | -1.1x | 2.6x | -0.6x | 0.5x | -0.1x | 0.5x | -0x |
| Capitalization / Revenue | 1,402x | 144x | 105x | 81x | 21.7x | 21.7x | 6.04x | 2.2x |
| EV / Revenue | 1,038x | 132x | 90.8x | 74.5x | 19.1x | 20.3x | 5.9x | 1.63x |
| EV / EBITDA | -40.4x | -88.2x | -25.7x | -20.6x | -24.9x | -30.5x | -95.6x | 2.82x |
| EV / EBIT | -35.8x | -38.8x | -25.2x | -20.2x | -22.6x | -26.3x | -63.1x | 2.89x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 1 | 2 | 3 |
| Rate of return | - | - | - | - | - | 19.5% | 38.9% | 58.4% |
| EPS 2 | -0.33 | -0.45 | -0.4 | -0.55 | -0.23 | -0.23 | -0.2176 | 0.51 |
| Distribution rate | - | - | - | - | - | -238% | -919% | 588% |
| Net sales 1 | 0.175 | 3.096 | 2.951 | 4.406 | 8.458 | 8.832 | 23.83 | 65.45 |
| EBITDA 1 | -4.494 | -4.634 | -10.44 | -15.89 | -6.482 | -5.889 | -1.471 | 37.76 |
| EBIT 1 | -5.075 | -10.54 | -10.64 | -16.24 | -7.13 | -6.808 | -2.228 | 36.84 |
| Net income 1 | -7.145 | -11.58 | -10.77 | -15.76 | -6.342 | -6.334 | -7.678 | 12.82 |
| Net Debt 1 | -63.84 | -38.25 | -43.04 | -28.94 | -21.78 | -12.16 | -3.3 | -37.5 |
| Reference price 2 | 9.500 | 17.300 | 11.600 | 12.750 | 6.540 | 5.140 | 5.140 | 5.140 |
| Nbr of stocks (in thousands) | 25,833 | 25,833 | 26,800 | 28,000 | 28,000 | 28,000 | 28,000 | - |
| Announcement Date | 3/9/21 | 3/16/22 | 3/15/23 | 2/29/24 | 4/30/25 | 3/26/26 | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.14x | 14.26x | -15.35x | - | 167M | |
| 29.97x | 10.87x | 22.45x | 0.67% | 909B | |
| 24.58x | 5.67x | 15.42x | 2.32% | 552B | |
| 26.01x | 6.42x | 13.1x | 3.21% | 375B | |
| 17.42x | 4.36x | 10.74x | 3.04% | 332B | |
| 23.41x | 4.86x | 13.71x | 1.79% | 291B | |
| 20.86x | 5.6x | 13.6x | 3.02% | 287B | |
| 50.97x | 4.77x | 19.37x | 2.93% | 279B | |
| 13.02x | 4.78x | 9.76x | 3.88% | 199B | |
| 21.5x | 5.81x | 10.16x | 3.05% | 179B | |
| Average | 21.56x | 6.74x | 11.29x | 2.66% | 340.33B | |
| Weighted average by Cap. | 26.39x | 6.82x | 16.00x | 2.24% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- HYL Stock
- Valuation Hyloris Pharmaceuticals SA
Select your edition
All financial news and data tailored to specific country editions
